US2021002347A1PendingUtilityA1
Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptors and adaptors thereof
Est. expiryOct 19, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 35/00A61K 2039/57C12N 2510/00A61P 37/04C07K 14/70578Y02A50/30C07K 14/705C12N 9/14
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing pattern recognition receptor activity, and CD40 activity. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing CD40 activity without prostaglandin E2. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible chimeric molecule comprising a region of a pattern recognition receptor or an adaptor thereof.
Claims
exact text as granted — not AI-modified1 .- 23 . (canceled)
24 . A nucleic acid comprising a polynucleotide that encodes a chimeric protein, wherein the chimeric protein comprises:
(a) a ligand binding region comprising two FKBP12(v36) polypeptides; (b) a MyD88 polypeptide region; and (c) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain, wherein the ligand binding region is amino terminal to the CD40 cytoplasmic polypeptide region of the chimeric protein.
25 . The nucleic acid of claim 24 , wherein the ligand binding region comprises Fv′Fvls.
26 . The nucleic acid of claim 24 , wherein the CD40 cytoplasmic polypeptide region is encoded by a polynucleotide sequence in SEQ ID NO: 1.
27 . The nucleic acid of claim 24 , wherein the nucleic acid is a viral vector.
28 . The nucleic acid of claim 24 , wherein the nucleic acid is a plasmid vector.
29 . The nucleic acid of claim 24 , wherein the nucleic acid comprises a promoter sequence operably linked to the polynucleotide.
30 . The nucleic acid of claim 24 , wherein the chimeric protein comprises a membrane targeting region.
31 . The nucleic acid of claim 30 , wherein the membrane targeting region is a myristoylation targeting region.Join the waitlist — get patent alerts
Track US2021002347A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.